The MLN-TK with ETV6::ABL1 shares common clinicopathological features with chronic myeloid leukemia, such as eosinophilia and response to tyrosine kinase inhibitor (TKI) therapy, due to the structural and functional similarity of the fusion proteins [5–8]. Here, TKT is linked to Increased total eosinophil count.